Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Pfizer restructuring leaves Geno Germano out of a job |
||||||||||||||||||
Geno Germano, Pfizer's ($PFE) global head of innovative pharma, is parting ways with the company as it restructures in preparation to merge with Allergan ($AGN). Germano joined Pfizer from Wyeth, where he served as president of the U.S. business and pharmaceutical business units. This week, Pfizer announced that Albert Bourla will run the combined drugs and vaccines unit following the merger, leaving Germano out of a job. Allergan's Brent Saunders will lead commercial operations as president and COO. Former Allergan EVP Bill Meury will lead specialty and consumer brands, a group that combines Allergan's eye products and aesthetics with Pfizer's consumer healthcare unit. At Pfizer, Germano was also a co-chair of the Portfolio Strategy and Investment Committee, focusing on maximizing R&D investment return, and managed the Global Health and Value function. He previously served as Pfizer's president and GM of specialty care and oncology. Story | Release
|